- cafead   Sep 25, 2018 at 07:32: PM
via Favorable cash repatriation rates and regulatory approvals for major healthcare deals have not brought an expected surge in mega-mergers among large US pharmaceutical companies, according to healthcare investment bankers.
article source
article source